Druggability & Clinical Context
Druggability
Low
Score: 0.41
Druggability Analysis
Structural Tractability0.85
Key Metrics
PDB Structures:
38
Known Drugs:
1
Approved:
0
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Preclinical
Therapeutic Areas:Mucolipidosis type IV Lysosomal storage disorders Neurodegeneration Autophagy-related diseases Lysosomal dysfunction disorders
Druggability Rationale: MCOLN1 presents moderate druggability (0.60) with strong structural support from 38 PDB structures at 2.1 Å resolution and cryo-EM data, enabling rational design of small molecule modulators. The existence of ML-SA1 as a validated research tool demonstrates feasibility, though ion channels typically present challenges with shallow binding pockets and potential selectivity issues across TRP channel family members.
Mechanism: Small molecule agonists or modulators of lysosomal calcium channel activity
Drug Pipeline (1 compounds)
1 Preclinical
Known Drugs:ML-SA1 (research_tool) — Lysosomal storage disorders
Structural Data:PDB (38) ✓AlphaFold ✓Cryo-EM ✓
Binding Pocket Analysis:Structural data suggests potential allosteric modulation sites distinct from the ion conduction pore, as evidenced by ML-SA1's agonist mechanism; high-resolution structures indicate multiple druggable pockets suitable for small molecule engagement, though the exact binding mode of current agonists remains under investigation.
Selectivity & Safety Considerations
Selectivity is a key challenge given MCOLN1's structural homology to other TRP channel family members (TRPML2, TRPML3); achieving selectivity will require targeting unique structural features or allosteric sites specific to MCOLN1. Off-target effects on related ion channels could cause unwanted lysosomal dysfunction in peripheral tissues.